Valuation: Alkermes plc

Market Cap 9.18B 8.06B 7.44B 6.96B 13.03B 867B 13.32B 89.33B 34.55B 428B 34.47B 33.72B 1,485B P/E 2026 *
-139x
P/E 2027 * 94.5x
Enterprise Value 10.14B 8.91B 8.22B 7.69B 14.39B 957B 14.71B 98.69B 38.16B 472B 38.08B 37.25B 1,641B EV / Sales 2026 *
5.6x
EV / Sales 2027 * 5.22x
Free-Float
89.39%
Yield 2026 *
-
Yield 2027 * -
1 day+4.26%
1 week+22.43%
Current month+30.55%
1 month+37.91%
3 months+87.41%
6 months+93.33%
Current year+96.85%
1 week 45.47
Extreme 45.47
55.28
1 month 40.62
Extreme 40.62
55.28
Current year 27
Extreme 27
55.28
1 year 25.16
Extreme 25.165
55.28
3 years 22.01
Extreme 22.01
55.28
5 years 21.24
Extreme 21.24
55.28
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 64 01/02/1991
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 74 26/05/2016
Director/Board Member 63 30/03/2018
Date Insider Type Main position Quantity % Market Cap.
06-12Sell

Director

-2,000 0.0012%
06-04Sell

Compliance Officer

-2,034 0.0012%
06-01Fiscal year

Chief Technology Officer

19,000 0.0114%
Change 5-day change 1-year change 3-year change Capi.($)
+4.26%+22.43%+91.18%+68.65% 9.18B
-0.48%+7.20%-5.65%+1.02% 46.2B
+2.19%+11.71%+393.31%+580.42% 38.71B
+2.53%+13.93%+21.38%-12.81% 31.9B
+1.65%+3.61%+16.04%+55.62% 31.12B
-4.16%-2.58%+8.94%+26.14% 23.77B
-0.32%+12.96% - - 16.2B
+1.37%+14.53%+69.64%+130.07% 15.05B
+1.00%+10.30%+13.31%+20.31% 13.74B
+3.63%+9.53%+103.97%+98.73% 13.42B
Average +1.17%+10.43%+79.13%+107.57% 23.93B
Weighted average by Cap. +0.89%+9.16%+88.85%+128.42%

Financials

2026 *2027 *
Net sales 1.81B 1.59B 1.47B 1.37B 2.57B 171B 2.63B 17.62B 6.82B 84.38B 6.8B 6.65B 293B 1.89B 1.66B 1.53B 1.43B 2.68B 179B 2.74B 18.41B 7.12B 88.15B 7.11B 6.95B 306B
Net income -65.21M -57.29M -52.83M -49.43M -92.54M -6.16B -94.59M -635M -245M -3.04B -245M -240M -10.55B 106M 93.26M 86.01M 80.47M 151M 10.02B 154M 1.03B 399M 4.95B 399M 390M 17.18B
Net Debt 961M 844M 779M 729M 1.36B 90.73B 1.39B 9.35B 3.62B 44.78B 3.61B 3.53B 156B 702M 616M 568M 532M 995M 66.21B 1.02B 6.83B 2.64B 32.68B 2.63B 2.58B 113B
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
26/06/26 $55.08 +4.26% 7,563,601
25/06/26 $52.83 +4.72% 3,249,672
24/06/26 $50.45 +4.95% 3,726,629
23/06/26 $48.07 +4.45% 2,451,924
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
55.08USD
Average target price
48.12USD
Spread / Average Target
-12.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock